Product Pipeline


Introducing RLS-C2203, Reliis’ ultra-pure Medicinal CBD formulation. Our advanced oral liquid cannabinoid product offers unparalleled purity, stability, and manufacturing reproducibility, setting a new standard in CBD therapeutics. With no THC, odour, or taste, RLS-C2203 enhances patient tolerability and compliance, simplifying prescription and administration.

TGA-approved via the Special Access Scheme (SAS) and Authorised Prescribers (AP) pathways, RLS-C2203 has completed Phase II clinical trials in cancer patients, demonstrating safety and excellent tolerability. As one of the few CBD products to undergo rigorous clinical testing, it opens doors to multiple clinical indications with vast market potential.

In a rapidly growing global market estimated at AUD$80 billion, RLS-C2203 stands at the forefront of medicinal cannabis innovation. In Australia alone, where legal prescriptions have been available since 2016, the market continues to expand, with significant increases in prescribers and approvals.

With CBD’s wide-ranging therapeutic potential, from pain management to improved sleep and mood, RLS-C2203 represents a transformative option for patients seeking natural remedies supported by clinical evidence. Join us in unlocking the full potential of CBD with Reliis’ Ultrapure Medicinal CBD (RLS-C2203).

Vaccine bottles and syringe injection. Medicine in ampoules.


Successful treatment and management of agitated delirium, a condition that presents as a state of mental confusion, restlessness, and agitation often occurs in medical settings, particularly in critically ill or hospitalised patients is limited.


Following major surgery, patients often experience hypotension requiring ICU admission, but many cannot take oral tablets due to their surgical condition. Reliis addresses this challenge with its innovative product, RLS-M2202.


The Intranasal Actuator Device developed by Reliis is set to be a groundbreaking medical device designed to address the unmet clinical need for fast and accurate drug delivery, particularly in patient groups where intravenous (IV) access is challenging or not feasible.

Contact Us

Head Office

Unit 14/127 Herdsman Parade Wembley, WA 6018


Contact Us

Head Office

Unit 14/127 Herdsman Parade Wembley, WA 6018